Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 28, 2004. The report details a share repurchase transaction executed on September 27, 2004, and discloses changes in directors' share interests.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback:
- Shares Purchased: 840,000 Ordinary shares.
- Purchase Price: 1,175.83 pence per share.
- Treasury Holdings: 47,183,000 shares held in Treasury following the transaction.
- Shares in Issue: 5,887,972,277 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through the repurchase of 840,000 shares, which are now held in Treasury. Additionally, minor changes in beneficial interests were recorded for four directors (Sir Christopher Hogg, Mr J D Coombe, Mrs G A Coombe, and Sir Peter Job) via Personal Equity Plan purchases on September 27, 2004.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total cost of the 840,000 share repurchase against the stated price of 1,175.83 pence.
- Confirm the updated total share count and Treasury holdings in subsequent filings.
- Review the authority granted at the Annual General Meeting on May 17, 2004, to ensure the repurchase was within approved limits.
- Note that this filing does not contain quarterly or annual financial performance data.